Navigation Links
AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
Date:8/15/2013

Dallas, TX (PRWEB) August 15, 2013

Key R&D trends in the Acute Myeloid Leukemia market include developing therapies for the patients with greatest unmet need, particularly the elderly, developing combination therapies, and investigating new targets (i.e. FLT3) involved in the pathogenesis of AML. Despite high levels of unmet need, uptake of new drugs will be limited, as KOLs are relatively unimpressed by these agents. Therefore, ample market opportunity will remain at the end of the forecast period. To circumvent historical difficulties with regulatory approval, companies are designing early- and late-stage clinical trials more rigorously. Randomization of early-stage trials is critical, and the designation of overall survival (OS) as the primary endpoint of pivotal studies is mandatory. Despite the hype around FLT3 inhibitors, KOLs are unconvinced that these drugs will be successful as monotherapies in AML.

This new research report published in Aug 2013, “OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017” ( http://www.reportsnreports.com/reports/267301-opportunityanalyzer-acute-myeloid-leukemia-aml-opportunity-analysis-and-forecasts-to-2017.html ), focuses on the remaining opportunity in AML exclusive of the acute promyleocytic leukemia (APL) subtype. The scope of this research includes: Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management; Topline AML therapeutics market revenue from 2012–2017. Annual cost of therapy, and peak pipeline drug sales of drugs launching during this forecast period are included; Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strate
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... from the National Institute of Standards and Technology ... demonstrated a new design for an atomic clock ... or a microcomb. , The microcomb clock, featured ... the new journal Optica ,* is the ... and its accurate conversion of optical frequencies to ...
(Date:7/22/2014)... July 22, 2014 CTD Holdings, Inc. ... pharmaceutical, medical device, cosmetics, and other markets, announced today ... a group of qualified private investors led by Novit ... , The transaction involved the signing of a ... shares of Common Stock at a price per share ...
(Date:7/22/2014)... NJ (PRWEB) July 22, 2014 ... precision, portable, and mechanical balances and scales, proudly ... balances has won Laboratory Equipment magazine’s 2014 “Readers' ... the second consecutive year the Explorer was voted ... The annual Readers’ Choice Awards celebrates “excellence in ...
(Date:7/22/2014)... and SHENZHEN, China , July ... LTD, (BGI Tech), a subsidiary of BGI, the ... launch of a new human whole exome sequencing ... newly offered service includes in-depth bioinformatics analysis and ... until December 31, 2014. Complete ...
Breaking Biology Technology:'Comb on a chip' powers new NIST/Caltech atomic clock design 2CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3
... 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a ... affordable vaccines based on proprietary manufacturing technologies and ... been awarded a proof of concept contract by ... laboratory specifically the Edgewood Chemical Biological Center ("ECBC") ...
... Guacamole is a little prettier in October as your ... "Pink" Guacamole. Nielsen-ranked, top-selling Wholly Guacamole, is for the ... proceeds from October "PINK" sales to help fight for ... of Texas-Based Wholly,s support for National Breast Cancer Awareness ...
... ... ... October 8, 2009 -- iCardiac Technologies, Inc., a global leader in advanced cardiac core ... iCardiac a comprehensive cardiac safety study. iCardiac will provide end-to-end study management, equipment ...
Cached Biology Technology:Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy 2Grocery Produce Fighting for a Cause - Wholly 'Pink' Guacamole 2Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2
(Date:7/23/2014)... fatty acids and energy to infants and children ... that soybean-based emulsions could compromise immune functions and ... lipid emulsions based on triglyceride oil, fish oil, ... this concern. , However, researchers at Rutgers and ... according to a review published today in the ...
(Date:7/22/2014)... consists of both still images and video of ... research. Forty-four still images were chosen from more ... staff, and alumni representing more than 25 different ... than 50 submissions. , Zach Donnell, a graduate ... 2014 organizers, noted that the exhibit highlights the ...
(Date:7/22/2014)... BEDFORD, Mass., July 22, 2014 Aware, Inc. (NASDAQ: ... and services, today reported financial results for its second quarter ... quarter of 2014 was $6.8 million, an increase of 53% ... Operating income before patent related income in the second quarter ... the second quarter of 2013. The increase in revenue and ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... be taken during radiation therapy treatments because they ... normal prostate cell lines, leading to normal tissue ... issue of the International Journal of Radiation ... Society for Radiation Oncology (ASTRO). Many prostate cancer ...
... The Society for Nutrition Education (SNE) has ... American Society for Nutrition (ASN) to publish a ... American Society for Nutrition, and Society for Nutrition ... Adults," focusing on access to safe and adequate ...
... This release is available in Spanish . ... found in South America that can cause terrible, Ebola-like ... Now, Howard Hughes Medical Institute (HHMI) researchers ... hemorrhagic fever virus latches onto and infects human cells, ...
Cached Biology News:Dietary supplements discouraged for prostate cancer patients 2Nutrition services for older adults at home and in communities 2New ways to disarm deadly South American hemorrhagic fever viruses 2New ways to disarm deadly South American hemorrhagic fever viruses 3
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Biology Products: